Transforaminal Epidural Injection in Acute Sciatica
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Patients suffering from sciatica are treated conservatively for the first 8 weeks due to the favourable prognosis. This period is preferably extended up to 14-16 weeks after which patients may opt for surgery. However, patients may experience severe discomfort due to pain in the leg which can lead to decreased physical activity and socio-economic problems. An adequate therapy to alleviate symptoms during this period of 'wait-and-see' is lacking. In this study, patients will be randomized to treatment with transforaminal epidural injections or standard oral pain medication.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Diagnosed with sciatica by GP
• NRS leg pain of 6 or more on a 10-point NRS scale
• Minimum duration of symptoms of 3 weeks and maximum duration of 8 weeks
Locations
Other Locations
Netherlands
Spaarne Gasthuis
RECRUITING
Haarlem
Spaarne Gasthuis
RECRUITING
Hoofddorp
Contact Information
Primary
Carmen LA Vleggeert-Lankamp, MD Msc Ph.D
cvleggeert@lumc.nl
+31715262109
Backup
Eduard JA Verheijen, Bsc
e.j.a.verheijen@lumc.nl
+31715262109
Time Frame
Start Date: 2019-06-01
Estimated Completion Date: 2026-07
Participants
Target number of participants: 142
Treatments
Experimental: Transforaminal Epidural Injection
Transforaminal Epidural Injection containing 1,5 mL lidocaine 2% and 40mg methylprednisolone acetate for injections L3 or below Transforaminal Epidural Injection containing 1,5 mL lidocaine 1% and 10mg dexamethasone for injections above L3
No_intervention: Oral pain medication
Patients will receive oral pain medication according to general practitioner guidelines.
Related Therapeutic Areas
Sponsors
Collaborators: Posthumus Meyjes Fonds, Stichting Achmea Gezondheidszor, Spaarne Gasthuis
Leads: C.L.A.Vleggeert-Lankamp